PHASE II STUDY OF ERLOTINIB AS A FIRST-LINE THERAPY FOR NON-SMALL-CELL LUNG CANCER PATIENTS ACCORDING TO THEIR CLINICAL PREDICTORS

被引：0
作者：
Lee, D. H. [1 ]
Kim, H. T. [2 ]
Kim, S. [1 ]
Suh, C. [1 ]
Lee, J. [1 ]
机构：
[1] Asan Med Ctr, Dept Internal Med, Div Oncol, Seoul, South Korea
[2] Natl Canc Ctr, Res Inst & Hosp, Ctr Lung Canc, Goyang, South Korea
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
[41]   First-line immunotherapy in advanced non-small-cell lung cancer [J].
Noronha, Vanita ;
Mehta, Prashant ;
Malik, Prabhat Singh ;
Patel, Amol .
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2019, 40 (04) :461-462
[42]   Is erlotinib for first-line use in EGFR plus non-small-cell lung cancer cost-effective? [J].
Veenstra, David L. ;
Bajaj, Preeti S. ;
Carlson, Josh John ;
Goertz, Hans-Peter .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[43]   Cisplatin and weekly docetaxel as first-line therapy in patients with advanced non-small cell lung cancer a phase II study [J].
Tartarone, A ;
Romano, G ;
Iodice, G ;
Capobianco, A ;
Coccaro, M ;
Bochicchio, A ;
Di Leo, P ;
Ardito, R ;
Di Renzo, N .
TUMORI, 2005, 91 (02) :131-134
[44]   A PHASE II STUDY OF FIRST-LINE BORTEZOMIB (B) IN PATIENTS (PTS) WITH STAGE IIIB/IV NON-SMALL-CELL LUNG CANCER (NSCLC) [J].
Planchard, D. ;
Besse, B. ;
Meric, J. B. ;
Veillard, A. S. ;
Pignon, J. P. ;
Chan, K. ;
Mathiot, C. ;
Lumbroso, J. ;
Lafontaine, C. ;
Soria, J. C. .
ANNALS OF ONCOLOGY, 2008, 19 :96-96
[45]   A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations [J].
Wang, Pingli ;
Cao, Liming ;
Tian, Panwen ;
Ren, Shengxiang ;
Miao, Liyun ;
Zhou, Chengzhi ;
Fan, Yun ;
Li, Yuping ;
Lv, Dongqing ;
Zhao, Xin ;
Yang, Mei ;
Zhu, Chaonan ;
Yu, Bing ;
Xu, June ;
Song, Yong ;
Wang, Kai .
CANCER COMMUNICATIONS, 2023, 43 (09) :1059-1063
[46]   Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study [J].
Rusthoven, JJ ;
Eisenhauer, E ;
Butts, C ;
Gregg, R ;
Dancey, J ;
Fisher, B .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1194-1199
[47]   Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503) [J].
Brahmer, J. R. ;
Lee, J. W. ;
Traynor, A. M. ;
Hidalgo, M. M. ;
Kolesar, J. M. ;
Siegfried, J. M. ;
Guaglianone, P. P. ;
Patel, J. D. ;
Keppen, M. D. ;
Schiller, J. H. .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (02) :302-308
[48]   Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study [J].
Chu, T. ;
Zhang, W. ;
Zhang, B. ;
Zhong, R. ;
Shi, C. ;
Zhang, X. ;
Qian, J. ;
Han, B. .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S589-S590
[49]   Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer [J].
Xu, Bei ;
Liu, Peng ;
Yin, Yongmei ;
Liu, Ping ;
Shu, Yongqian .
BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (08) :763-769
[50]   Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer [J].
Patel, Jyoti D. ;
Hensing, Thomas A. ;
Rademaker, Alfred ;
Hart, Eric M. ;
Blum, Matthew G. ;
Milton, Daniel T. ;
Bonomi, Philip D. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3284-3289
12345